

CTAC
Pancreatic Ductal Adenocarcinoma
(PDAC) Progress Working Group

Interim Report

James L. Abbruzzese

July 8, 2015

Working Group's Purpose & Objectives

The primary purpose of the PDAC Progress WG is to monitor NCI's progress of the Scientific Framework sent to Congress in February of 2014.

The Working Group's main objectives are as follows:

- Assess NCI progress to date (*short term*)
- Provide recommendations for process of future annual assessment reports to CTAC (*intermediate term*)
- Review and update the scientific framework no later than 5 years after initial development (*long term*)
- Submit a report to Congress on the effectiveness of the scientific framework no later than 6 years after the initial development (*long term*)

Scientific Framework's Four Initiatives & the Subgroups' Assignments

- Initiative 1: Understanding the Biological Relationship between PDAC and Diabetes Mellitus (DM)
 - Rachael Stolzenberg-Solomon*, Jim Abbruzzese, Dana Andersen, Jane Holt, Murray Korc, Gloria Petersen, Sudhir Srivastava
- Initiative 2: Early Detection and Biomarkers
 - Gloria Petersen*, James Abbruzzese, Tony Hollingsworth, Jane Holt, Alison Klein, Murray Korc, David Mankoff, Lynn Matrisian, Sheila Prindiville, Sudhir Srivastava
- Initiative 3: New Therapeutic Strategies in Immunotherapies
 - Elizabeth Jaffee*, Jim Abbruzzese, Christine Alewine, Toby Hecht, Tony Hollingsworth, Jane Holt, Andrew Lowy
- Initiative 4: Development of RAS Therapeutics
 - Lynn Matrisian*, Debbie Jaffe, Murray Korc, Andrew Lowy, Sudhir Srivastava, David Tuveson

* Subgroups' Facilitators

Scientific Framework's Implementation Process: Initial Impressions

- **All of the initiatives within the Scientific Framework are still relevant**
- **Initiative 1 (Relationship between PDAC and DM):**
Implementation progress is on target
 - NIDDK/NCI RFA for a Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer released, grants submitted, review scheduled for Summer 2015, funding FY 2016
 - NIDDK/NIBIB meeting, “Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease” July 22, 2015
- **Initiative 2 (Early Detection and Biomarkers):**
Implementation progress is on target
 - NCI PAR 15-289, “The Pancreatic Cancer Detection Consortium (U01) published June 30, 2015 ; <http://grants.nih.gov/grants/guide/pa-files/PAR-15-289.html>

Scientific Framework's Implementation Process: Initial Impressions

- **Initiative 3 (Immunotherapy):**

Implementation plan needs further assessment

- Initiative would benefit from an additional meeting

- **Initiative 4 (Development of Ras Therapeutics):**

Implementation plan has been launched; however, additional information is needed to assess progress

- Learn more about FNLCR RAS project and relevance to PDAC

Next Steps

- Webinar with the entire Working Group to finalize recommendations from the initial review – *July 16, 2015*
- Distribute working group report to CTAC – *November 4, 2015*

Progress in PDAC WG Members

Chair: James Abbruzzese

Members:

Christine Alewine

Dana Andersen

Michael (Tony) Hollingsworth

Jane M. Holt

Elizabeth Jaffee

Alison Klein

Murray Korc

Andrew Lowy

David Mankoff

Lynn Matrisian

Gloria Petersen

Rachel Stolzenberg-Solomon

David Tuveson

NIH Liaisons:

Jeffrey Abrams

Dana Andersen

Amy Bulman

James Doroshow

Sarah Fabian

Samantha Finstad

Toby Hecht

Deborah Jaffe

LeeAnn Jensen

Bhupinder Mann

Sheila Prindiville

Sudhir Srivastava